Clinical trial Recruiting at 19 sites Phase 3 Interventional Ages Any age to 17

Examining blood transfusion methods for children with severe bleeding

Official title: Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding

Run by University of Pittsburgh · NCT06070350 · Data updated 2026-11-12

This study is testing whether using a specific type of blood and a medication can help children with severe bleeding from injuries survive better than standard treatments.

Quick facts

PhasePhase 3
Study typeInterventional
AgesAny age to 17 Years
SexAll
Enrollment1000 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Locations23 sites (Tucson, Arizona and 22 other locations)
StatusRecruiting
StartedNovember 1, 2024
Main results expectedJune 1, 2028
Study endsOctober 1, 2028
Registry record updatedSeptember 17, 2026
Trial IDNCT06070350 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children under 18 years old with confirmed or suspected active life-threatening traumatic bleeding.

Probably not a fit

Patients with devastating traumatic brain injuries not expected to survive or those who have not received blood products may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MATIC-2 trial is a multicenter, phase III clinical trial focused on children under 18 years old who are experiencing hemorrhagic shock due to traumatic injuries. It aims to compare the effectiveness of Low Titer Group O Whole Blood (LTOWB) against component therapy (CT) and Tranexamic Acid (TXA) against a placebo in reducing 24-hour all-cause mortality. Participants will be randomized to receive either LTOWB or CT, and TXA or placebo, with the study also assessing safety outcomes related to these interventions. The trial employs a Bayesian adaptive design to enhance its efficiency and responsiveness.

Why it matters

Potential benefit: If successful, this study could significantly reduce mortality rates in children suffering from traumatic life-threatening hemorrhage.

How similar studies have gone: Other studies have shown promise in using whole blood for transfusions, but this specific approach is novel and untested in this pediatric population.

Who can join: the full rules

Show full inclusion / exclusion criteria
General Inclusion Criteria:

1. Children, defined as less than estimated18 years of age with traumatic injury
2. MTP activation for confirmed or suspected active life-threatening traumatic bleeding

AND

Confirmed or suspected active life-threatening traumatic bleeding with at least 2 of 3 of the following criteria:

1. Hypotension for age (\< 5% tile)
2. Tachycardia for age (\>95th % tile)
3. Traumatic injury with exam findings consistent with severe bleeding (e.g., penetrating injury, hemothorax, distended abdomen with bruising, amputation of limb).

General Exclusion Criteria:

1. Patient with devastating traumatic brain injury not expected to survive due to magnitude of injury (example: Transhemispheric gunshot wound with signs of herniation, GCS score of 3 with fixed and dilated pupils)
2. MTP activated but no blood products given
3. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
4. Patients who are known or suspected to be pregnant on clinical examination
5. Known prisoners as defined in protocol
6. Known ward of the state
7. Isolated hanging, drowning or burns
8. Previous enrollment in MATIC-2
9. Prior study opt-out with bracelet

Exclusion Criteria for the TXA/Placebo Domain

1. Prehospital or pre-enrollment use of TXA
2. Greater than 3 hours since time of injury
3. History of seizure after the injury event
4. Known allergy or hypersensitivity reaction to TXA

Where it's running

  • University of Arizona
    Tucson, Arizona, United States
    Recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas, United States
    Recruiting
  • University of California Davis
    Sacramento, California, United States
    Recruiting
  • Children's National Hospital
    Washington D.C., District of Columbia, United States
    Recruiting
  • Emory University-Arthur M. Blank Hospital
    Atlanta, Georgia, United States
    Recruiting
  • University of Mississippi Medical Center
    Jackson, Mississippi, United States
    Recruiting
Show 17 more locations
  • Washington University of St. Louis
    St Louis, Missouri, United States
    Recruiting
  • University of New Mexico
    Albuquerque, New Mexico, United States
    Recruiting
  • Wake Forest University Health Sciences
    Wake Forest, North Carolina, United States
    Recruiting
  • Nationwide Children's Hospital
    Columbus, Ohio, United States
    Recruiting
  • Oregon Health and Science University
    Portland, Oregon, United States
    Recruiting
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • LeBonheur Children's Hospital
    Memphis, Tennessee, United States
    Recruiting
  • Baylor College of Medicine
    Houston, Texas, United States
    Recruiting
  • Children's Memorial Hermann Hospital
    Houston, Texas, United States
    Recruiting
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas, United States
    Recruiting
  • Primary Children's Hospital
    Salt Lake City, Utah, United States
    Recruiting
  • University of Washington Harborview
    Seattle, Washington, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Recruiting
  • Emory University-Scottish Rite Hospital
    Atlanta, Georgia, United States
    Terminated
  • Tulane School of Medicine
    New Orleans, Louisiana, United States
    Withdrawn
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Not yet recruiting
  • The University of Texas Southwestern Medical Center
    Dallas, Texas, United States
    Terminated

Study contacts

  • Principal investigator: Philip C Spinella, MD — Univesrity of Pittsburgh
  • Study coordinator: Thomas Byers
  • Email: tdb33@pitt.edu
  • Phone: 412-383-2340

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.